FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic analogue of growth hormone–releasing hormone (GHRH) engineered to extend the duration of pulsatile growth hormone (GH) stimulation [1].
While short-acting GHRH analogues mimic the body’s natural rhythm in brief intervals, the DAC modification enables CJC-1295 to bind covalently to circulating albumin, dramatically increasing its half-life and sustaining its physiologic influence for days rather than hours [2].
This stability allows for consistent signaling through the GH–IGF-1 axis, which plays a central role in growth, tissue maintenance, and metabolic regulation [3].
This 30 amino acid peptide retains features of native GHRH but incorporates amino-acid substitutions that enhance resistance to enzymatic breakdown. When combined with DAC, these modifications create a formulation capable of maintaining elevated IGF-1 levels with infrequent administration.
CJC-1295 can provide extended support to endocrine pathways involved in cellular repair, lean-mass maintenance, and metabolic homeostasis.
The DAC modification helps the peptide to form a stable covalent bond with serum albumin, significantly prolonging its half-life compared to non-DAC formulations.
This prolonged activity allows for more sustained elevations in circulating IGF-1, a key mediator of anabolic and metabolic processes.
IGF-1 plays essential roles in protein synthesis, cellular repair, mitochondrial function, and nutrient partitioning. By maintaining higher IGF-1 concentrations over several days, CJC-1295 with DAC provides a longer, smoother signaling window that may enhance the body’s ability to support tissue maintenance and energy balance.
While short-acting GHRH analogues rely on frequent dosing to achieve measurable changes, the DAC-bound version generates a more gradual and durable physiological response.
This extended profile can:
While preserving the rhythmic qualities of GH secretion and broadening the duration of downstream effects.
An interventional clinical study of healthy adult men evaluated the effects of CJC-1295 on GH secretion parameters [4].
Participants received either 60 μg/kg or 90 μg/kg of a single subcutaneous injection of CJC-1295 with DAC. Participants then underwent 20-minute interval blood sampling over 12 hours overnight to characterize GH pulsatility.
Results showed that:
A single dose of CJC-1295 significantly increases basal (trough) GH secretion, leading to higher mean GH and IGF-1 levels, while keeping pulsatility intact.
CJC-1295 with DAC’s extended influence on the GH–IGF-1 axis can create a metabolic and anabolic environment that supports favorable shifts in body composition.
Growth hormone plays a central role in nutrient partitioning, encouraging the body to utilize fat as an energy substrate while preserving lean tissue. Through its prolonged stimulation of GH release and sustained elevation of IGF-1, CJC-1295 with DAC can reinforce pathways associated with [5]:
IGF-1 is particularly significant in this context, as it is involved in regulating:
By maintaining more consistent IGF-1 levels over time, CJC-1295 with DAC may help the body support muscle maintenance and gradual increases in lean mass, especially when combined with resistance training or periods of heightened physical demand.
Currently however, no human trials exist that evaluate these potential effects. A previous study did attempt to characterize whether CJC 1295 can reduce visceral fat in HIV patients with pathologic lipodystrophy [8].
However, after the death of a participant due to HIV itself, the trial was discontinued, with no data published.
Although there is some volume of anecdotal evidence of online users self-administering CJC 1295 for weight loss, regulated human studies need to be established to validate these theoretical applications.
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
— Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). CJC 1295 with DAC is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
